Increased circulating urocortin-3 levels is associated with polycystic ovary syndrome

References

• Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;8:41
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90:5711–16
   PubMed Web of Science ®Google Scholar
• Meyer C, McGrath BP, Cameron J, et al. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4630–5
   PubMed Web of Science ®Google Scholar
• Tarkun I, Arslan BC, Cantürk Z, et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004;89:5592–6
   PubMed Web of Science ®Google Scholar
• van der Meulen T, Huising MO. Maturation of stem cell-derived beta-cells guided by the expression of urocortin 3. Rev Diabet Stud 2014;11:115–32
   PubMedGoogle Scholar
• van der Meulen T, Donaldson CJ, Cáceres E, et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat Med 2015;21:769–76
   PubMed Web of Science ®Google Scholar
• Li C, Chen P, Vaughan J, et al. Urocortin III is expressed in pancreatic beta-cells and stimulates insulin and glucagon secretion. Endocrinology 2003;144:3216–24
   PubMed Web of Science ®Google Scholar
• van der Meulen T, Xie R, Kelly OG, et al. Urocortin 3 marks mature human primary and embryonic stem cell-derived pancreatic alpha and beta cells. PLoS One 2012;7:e52181
   PubMed Web of Science ®Google Scholar
• Li C, Chen P, Vaughan J, et al. Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci USA 2007;104:4206–11
   PubMed Web of Science ®Google Scholar
• Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001;98:7570–5
   PubMed Web of Science ®Google Scholar
• Shorakae S, Teede H, de Courten B, et al. The emerging role of chronic low-grade inflammation in the pathophysiology of polycystic ovary syndrome. Semin Reprod Med 2015;33:257–69
   PubMed Web of Science ®Google Scholar
• Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011;335:30–41
   PubMed Web of Science ®Google Scholar
• Demir B, Cengiz H, Ungan I, et al. The relationship between epicardial adipose tissue thickness and oxidative stress parameters in patients with isolated polycystic ovary syndrome. Gynecol Endocrinol 2015;31:531–5
   PubMed Web of Science ®Google Scholar
• Moti M, Amini L, Mirhoseini Ardakani SS, et al. Oxidative stress and anti-oxidant defense system in Iranian women with polycystic ovary syndrome. Iran J Reprod Med 2015;13:373–8
   PubMedGoogle Scholar
• Mahajan S, Liao M, Barkan P, et al. Urocortin 3 expression at baseline and during inflammation in the colon: corticotropin releasing factor receptors cross-talk. Peptides 2014;54:58–66
   PubMed Web of Science ®Google Scholar
• Novembri R, Carrarelli P, Toti P, et al. Urocortin 2 and urocortin 3 in endometriosis: evidence for a possible role in inflammatory response. Mol Hum Reprod 2011;17:587–93
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25
   Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
   PubMed Web of Science ®Google Scholar
• Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome – a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007;92:4546–56
   PubMed Web of Science ®Google Scholar
• Dehdashtihaghighat S, Mehdizadehkashi A, Arbabi A, et al. Assessment of C-reactive protein and C3 as inflammatory markers of insulin resistance in women with polycystic ovary syndrome: a case-control study. J Reprod Infertil 2013;14:197–201
   PubMedGoogle Scholar
• Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 1997;15:111–22
   PubMedGoogle Scholar
• Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab 1995;80:3788–90
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001–15
   PubMed Web of Science ®Google Scholar
• O’Meara NM, Blackman JD, Ehrmann DA, et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1241–7
   PubMed Web of Science ®Google Scholar
• Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942–7
   PubMed Web of Science ®Google Scholar
• Jamieson PM, Cleasby ME, Kuperman Y, et al. Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet. Diabetologia 2011;54:2392–403
   PubMed Web of Science ®Google Scholar
• Yang S, Li Q, Song Y, et al. Serum complement C3 has a stronger association with insulin resistance than high sensitivity C-reactive protein in women with polycystic ovary syndrome. Fertil Steril 2011;95:1749–53
   PubMed Web of Science ®Google Scholar